Key facts
- This page summarizes Thomas Garner's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2024, 18:33.
Thomas Garner - 09 Dec 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- EVP, Chief Commercial Officer
- Issuer ticker
- ACAD
- Reported as of
- 09 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2024, 18:33:31 UTC
- Prior SEC filing
- 12 Feb 2024
- Next SEC filing
- 10 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Garner filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 10 Dec 2024.
Change
- Previous filing in this sequence was filed on 12 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +235,849
- Change %
- Price
- $0.000000
- Shares after
- 235,849
- Date
- 09 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 235,849
- Exercise price
- $18.76
- Footnotes
- F1
ACAD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +45,372
- Change %
- Price
- $0.000000
- Shares after
- 45,372
- Date
- 09 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,372
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
25% of the shares subject to the Stock Option granted under the 2024 Equity Incentive Plan (the "Plan") will vest and become exercisable on December 9, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
Footnote F2
Each restricted stock unit granted under the Plan represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
50% of the restricted stock units vest on December 9, 2026 and 25% vest on each of December 9, 2027 and December 9, 2028.